{"id":388994,"date":"2025-01-29T00:00:00","date_gmt":"2025-01-29T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0042-2024-biopharma-ulcerative-colitis-treatment-algorithms-claims-data-analysis-adult-us-2024\/"},"modified":"2026-05-25T23:11:49","modified_gmt":"2026-05-25T23:11:49","slug":"algoim0042-2024-biopharma-ulcerative-colitis-treatment-algorithms-claims-data-analysis-adult-us-2024","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0042-2024-biopharma-ulcerative-colitis-treatment-algorithms-claims-data-analysis-adult-us-2024\/","title":{"rendered":"Ulcerative Colitis | Treatment Algorithms: Claims Data Analysis | Adult | US | 2024"},"content":{"rendered":"<p>Ulcerative colitis (UC) is a chronic intermittent relapsing disorder of the large intestine and rectum. Treatment typically begins with conventional agents (e.g., 5-aminosalicylic acids [5-ASAs]) that are often effective for those patients with mild to moderate disease. Treatment then progresses to more-potent drugs, such as immunosuppressants and\/or biologics, as needed. Among the biologics, tumor necrosis factor (TNF)-alpha inhibitors (Janssen\u2019s Remicade and AbbVie\u2019s Humira), a cell adhesion molecule (CAM) inhibitor (Takeda\u2019s Entyvio), and an IL-12\/23 inhibitor (Janssen\u2019s Stelara) are the mainstays of treatment, followed by oral targeted therapies comprising Janus kinase (JAK) inhibitors (Pfizer\u2019s Xeljanz \/ Xeljanz XR and AbbVie\u2019s Rinvoq). However, later-to-market drugs, such as a sphingosine 1-phosphate receptor (S1P-R) modulators (BMS\u2019s Zeposia and Pfizer\u2019s Velsipity) and an IL-23 inhibitor (Eli Lilly\u2019s Omvoh), are increasing the market competition among later-line targeted therapies. Moreover, the availability of infliximab biosimilars and adalimumab biosimilars in the United States will further impact market dynamics.<\/p>\n<p>For the abstract please provide an overview paragraph here and then fill in the bulleted sections below. Feel free to modify the bulleted section. Leverage content from a brochure if you have one.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul>\n<li>What patient shares do key therapies and brands garner by line of therapy in newly diagnosed adult UC patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed adult UC patients?<\/li>\n<li>How have Rinvoq and Omvoh been integrated into the treatment algorithm, and what are their sources of business?<\/li>\n<li>What percentage of adult UC patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?<\/li>\n<li>What percentage of adult UC patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated patients?<\/li>\n<\/ul>\n<p><strong>Markets covered:<\/strong> United States<\/p>\n<p><strong>Key companies:<\/strong> AbbVie, Janssen, Pfizer, Takeda, UCB, BMS<\/p>\n<p><strong>Key drugs: <\/strong>Humira, Remicade, biosimilar infliximab, Entyvio, Stelara, Xeljanz \/ Xeljanz XR, Simponi, Zeposia, Rinvoq, aminosalicylates, immunosuppressants<\/p>\n<p><strong>Product description<\/strong><\/p>\n<p>Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.<\/p>\n<p><strong>Key feature<\/strong><\/p>\n<p>Dashboard featuring interactive visuals, easy navigation, and expanded analyses<\/p>\n","protected":false},"template":"","class_list":["post-388994","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-ulcerative-colitis","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/388994","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/388994\/revisions"}],"predecessor-version":[{"id":392130,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/388994\/revisions\/392130"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=388994"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}